Pfizer launches early safety trial for new kidney disease drug
NCT ID NCT06994897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new medicine called PF-07985631, which may one day treat a kidney disease called IgA nephropathy. About 92 healthy adults will receive either the study drug or a placebo as an injection or IV. The main goal is to check safety and how the body processes the drug, not to treat any illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Clinical Research Unit - Brussels
RECRUITINGBrussels, Bruxelles-capitale, Région de, B-1070, Belgium